The role of senescent cells in acquired drug resistance and secondary cancer in brafi-treated melanoma

Keyphrases

• Melanoma 100%
• Acquired Drug Resistance 100%
• Secondary Cancer 100%
• Senescent Cells 100%
• Disease Progression 50%
• Missense mutation 50%
• Malignant Melanoma 50%
• Mitogen-activated Protein Kinase 50%
• Pro-survival 50%
• BRAF Inhibitor (BRAFi) 50%
• Potential Gains 25%
• Drug Resistance 25%
• Adjuvant Therapy 25%
• Genetic Mechanism 25%
• Cellular Senescence 25%
• Senotherapeutics 25%
• Codon 25%
• Constitutive Activation 25%
• Causal Mechanisms 25%
• Kinase Domain 25%
• BRAF mutation 25%
• Secondary Resistance 25%
• BRAF Inhibitor Resistance 25%
• Melanoma Survival 25%
• Benign Nevus 25%
• Common Genes 25%
• BRAF V600 mutation 25%

Biochemistry, Genetics and Molecular Biology

• Missense Mutation 100%
• Protein Kinases 100%
• Drug Resistance 100%
• Genetic Mechanism 50%
• Upregulation 50%
• Mutated Genes 50%
• Codon 50%
• Phosphotransferase 50%
• Kinase 50%
• Carcinogenesis 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Drug Resistance 100%
• Mitogenic Agent 28%
• Protein Kinases 28%
• Nevus 14%
• Disease Exacerbation 14%
• Phosphotransferase 14%
• Carcinogenesis 14%
• Diseases 14%